{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:52:01Z","timestamp":1793317921570,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Science and Technology Development Project of Hangzhou","award":["202004A19"],"award-info":[{"award-number":["202004A19"]}]},{"name":"Science and Technology Development Project of Hangzhou","award":["202204A08"],"award-info":[{"award-number":["202204A08"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patient-derived tumor organoids (PDOs) hold immense potential for personalized drug sensitivity testing, but accurate efficacy determination is crucial for clinical translation. This study investigated factors influencing the accuracy and reproducibility of drug sensitivity measurements in PDOs, focusing on half-maximal-inhibitory-concentration (IC50) calculation methods, drug concentration numbers, and plate types. PDOs were established from six primary cancer tissues, including two cervical resections, one lung biopsy, one lung pleural effusion, one breast biopsy, and one gastric resection. They were subjected to drug sensitivity assays with 21 single\/combined treatments, encompassing chemotherapy and targeted therapy drugs, with concentrations standardized in fold. Utilizing 6- and 12-concentration setups, IC50 derived from GraphPad-Dose-response\u2013Inhibition (DRI), LC-logit, and LC-probit methods were compared. Relative changes (RCs) in IC50 and area-under-the dose-response-curve (AUC) between setups and the impact of plate type on cell viability measurements were assessed. In the 12-concentration setup, no significant IC50 differences were observed among the calculation methods. Notably, GraphPad-DRI and LC-logit exhibited minimal RCs between the 6- and 12-concentration setups (0.035 and \u22120.033, respectively), indicating accurate IC50 quantification even with fewer drug concentrations. AUC correlated strongly with GraphPad-DRI-derived IC50 (R\u2009=\u20090.858) and demonstrated lower variance between technical replicates. Furthermore, opaque-bottom plates yielded higher precision in cell viability measurements compared to transparent-bottom plates. This study provides valuable insights into optimizing drug sensitivity testing in PDOs. By demonstrating the robustness of specific IC50 calculation methods and the feasibility of using fewer drug concentrations, this study contributed to the standardization and reliability of PDO-based drug sensitivity assays.<\/jats:p>","DOI":"10.1093\/biomethods\/bpaf012","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T16:05:50Z","timestamp":1739462750000},"source":"Crossref","is-referenced-by-count":10,"title":["Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters"],"prefix":"10.1093","volume":"10","author":[{"given":"Yidan","family":"Chen","sequence":"first","affiliation":[{"name":"Hangzhou Cancer Institute, Hangzhou Cancer Hospital , Hangzhou, Zhejiang 310002,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine , Zhejiang 310006,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Kai","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of R&D, Hangzhou AimingMed Technologies Co., Ltd, Hangzhou 310000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of R&D, Hangzhou AimingMed Technologies Co., Ltd, Hangzhou 310000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of R&D, Hangzhou AimingMed Technologies Co., Ltd, Hangzhou 310000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Hangzhou Cancer Hospital , Hangzhou, Zhejiang 310002,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingliang","family":"You","sequence":"additional","affiliation":[{"name":"Department of R&D, Hangzhou AimingMed Technologies Co., Ltd, Hangzhou 310000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of R&D, Hangzhou AimingMed Technologies Co., Ltd, Hangzhou 310000,","place":["China"]},{"name":"Basic Medicine School, Chengdu University of Traditional Chinese Medicine , Chengdu 610000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Hangzhou Cancer Hospital , Hangzhou, Zhejiang 310002,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9455-3296","authenticated-orcid":false,"given":"Huayang","family":"Xing","sequence":"additional","affiliation":[{"name":"Hangzhou Cancer Institute, Hangzhou Cancer Hospital , Hangzhou, Zhejiang 310002,","place":["China"]},{"name":"Department of R&D, Hangzhou AimingMed Technologies Co., Ltd, Hangzhou 310000,","place":["China"]},{"name":"Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine , Chengdu 610000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2025030920114169500_bpaf012-B1","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","article-title":"Establishment of patient-derived cancer organoids for drug-screening applications","volume":"15","author":"Driehuis","year":"2020","journal-title":"Nat Protoc"},{"key":"2025030920114169500_bpaf012-B2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.gde.2013.11.012","article-title":"Organoid cultures for the analysis of cancer phenotypes","volume":"24","author":"Sachs","year":"2014","journal-title":"Curr Opin Genet Dev"},{"key":"2025030920114169500_bpaf012-B3","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"2025030920114169500_bpaf012-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmeth.4575","article-title":"Method of the Year 2017: organoids","volume":"15","year":"2018","journal-title":"Nat Methods"},{"key":"2025030920114169500_bpaf012-B5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2025030920114169500_bpaf012-B6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"key":"2025030920114169500_bpaf012-B7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"2025030920114169500_bpaf012-B8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s43018-022-00359-0","article-title":"Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors","volume":"3","author":"Herpers","year":"2022","journal-title":"Nat Cancer"},{"key":"2025030920114169500_bpaf012-B9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cell.2018.07.027","article-title":"Divergent routes toward Wnt and R-spondin Niche independency during human gastric carcinogenesis","volume":"174","author":"Nanki","year":"2018","journal-title":"Cell"},{"key":"2025030920114169500_bpaf012-B10","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/s41388-020-01492-9","article-title":"Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell","volume":"39","author":"Ukai","year":"2020","journal-title":"Oncogene"},{"key":"2025030920114169500_bpaf012-B11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1126\/science.adg6276","article-title":"FDA no longer has to require animal testing for new drugs","volume":"379","author":"Wadman","year":"2023","journal-title":"Science"},{"key":"2025030920114169500_bpaf012-B12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"key":"2025030920114169500_bpaf012-B13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"Sebaugh","year":"2011","journal-title":"Pharm Stat"},{"key":"2025030920114169500_bpaf012-B14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/0962280219832631","article-title":"Optimal designs for asymmetric sigmoidal response curves in bioassays and immunoassays","volume":"29","author":"Hyun","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"2025030920114169500_bpaf012-B15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2307\/2280078","article-title":"Probit analysis: a statistical treatment of the sigmoid response curve","volume":"43","author":"Merrell","year":"1948","journal-title":"J Am Stat Assoc"},{"key":"2025030920114169500_bpaf012-B16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/01621459.1947.10501927","article-title":"The use of the angular transformation in biological assays","volume":"42","author":"Knudsen","year":"1947","journal-title":"J Am Stat Assoc"},{"key":"2025030920114169500_bpaf012-B17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/jee\/toab044","article-title":"Comparison of lethal doses calculated using logit\/probit\u2013log(dose) regressions with arbitrary slopes using R","volume":"114","author":"Peng","year":"2021","journal-title":"J Econ Entomol"},{"key":"2025030920114169500_bpaf012-B18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.vetmic.2011.03.003","article-title":"Median infectious dose (ID50) of porcine reproductive and respiratory syndrome virus isolate MN-184 via aerosol exposure","volume":"151","author":"Cutler","year":"2011","journal-title":"Vet Microbiol"},{"key":"2025030920114169500_bpaf012-B19","doi-asserted-by":"crossref","first-page":"107116","DOI":"10.1016\/j.isci.2023.107116","article-title":"Cutoff value of IC50 for drug sensitivity in patient-derived tumor organoids in colorectal cancer","volume":"26","author":"Tang","year":"2023","journal-title":"iScience"},{"key":"2025030920114169500_bpaf012-B20","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025030920114169500_bpaf012-B21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-pathol-020712-163923","article-title":"Cellular heterogeneity and molecular evolution in cancer","volume":"8","author":"Almendro","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"2025030920114169500_bpaf012-B22","first-page":"1","author":"Francies","year":"2016"},{"key":"2025030920114169500_bpaf012-B23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.21147\/j.issn.1000-9604.2020.03.12","article-title":"An organoids biobank for recapitulating tumor heterogeneity and personalized medicine","volume":"32","author":"Yang","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"2025030920114169500_bpaf012-B24","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","article-title":"Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025030920114169500_bpaf012-B25","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the drugbank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2025030920114169500_bpaf012-B26","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2025030920114169500_bpaf012-B27","doi-asserted-by":"crossref","first-page":"101079","DOI":"10.1016\/j.xpro.2021.101079","article-title":"Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities","volume":"3","author":"Calandrini","year":"2022","journal-title":"STAR Protoc"},{"key":"2025030920114169500_bpaf012-B28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025030920114169500_bpaf012-B29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1631\/jzus.B2100701","article-title":"High-throughput \u201cread-on-ski\u201d automated imaging and label-free detection system for toxicity screening of compounds using personalised human kidney organoids","volume":"23","author":"Wang","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"key":"2025030920114169500_bpaf012-B30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13287-022-02902-3","article-title":"Assay establishment and validation of a high-throughput organoid-based drug screening platform","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2025030920114169500_bpaf012-B31","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"key":"2025030920114169500_bpaf012-B32","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.7150\/thno.96027","article-title":"Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development","volume":"14","author":"Xiang","year":"2024","journal-title":"Theranostics"}],"container-title":["Biology Methods and Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biomethods\/advance-article-pdf\/doi\/10.1093\/biomethods\/bpaf012\/61869390\/bpaf012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/10\/1\/bpaf012\/61869390\/bpaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/10\/1\/bpaf012\/61869390\/bpaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T20:12:51Z","timestamp":1741551171000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomethods\/article\/doi\/10.1093\/biomethods\/bpaf012\/8011372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/biomethods\/bpaf012","relation":{},"ISSN":["2396-8923"],"issn-type":[{"value":"2396-8923","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"bpaf012"}}